The Government Accountability Office recommends that FDA take steps to publicly disclose how it resolves conflict of interest and appearance issues for advisory committee members and invited speakers, to increase transparency and consistency.
Three experts express differing views on the reasons for and the impact of the departure of CBER director Vinay Prasad from FDA for a second time.
The Government Accountability Office recommends that FDA take steps to publicly disclose how it resolves conflict of interest and appearance issues for advisory committee members and invited speakers, to increase transparency and consistency.
Three experts express differing views on the reasons for and the impact of the departure of CBER director Vinay Prasad from FDA for a second time.
FDA sends a Warning Letter to ImmunityBio, citing misleading promotional claims about its cancer therapy Anktiva (nogapendekin alfa inbakicept-pmln) in both a television advertisement and a podcast appearance by company leadership.
A Brookings commentary warns that intense price competition in the U.S. generic drug market is undermining manufacturing quality and increasing the risk of shortages.
